Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature. Norum, J., Traasdahl, E. R., Totth, A., Nieder, C., & Olsen, J. A. Global Journal of Health Science, 8(4):1–9, 2015.
Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature [link]Paper  doi  bibtex   
@article{norum_health_2015-1,
	Author = {Norum, Jan and Traasdahl, Erik R. and Totth, Arpad and Nieder, Carsten and Olsen, Jan Abel},
	Doi = {10.5539/gjhs.v8n4p1},
	Journal = {Global Journal of Health Science},
	Number = {4},
	Pages = {1--9},
	Title = {Health {Economics} and {Radium}-223 ({Xofigo}{\textregistered}) in the {Treatment} of {Metastatic} {Castration}-{Resistant} {Prostate} {Cancer} ({mCRPC}): {A} {Case} {History} and a {Systematic} {Review} of the {Literature}},
	Url = {http://hdl.handle.net/10037/8612},
	Volume = {8},
	Year = {2015},
	Bdsk-Url-1 = {http://hdl.handle.net/10037/8612},
	Bdsk-Url-2 = {https://doi.org/10.5539/gjhs.v8n4p1}}

Downloads: 0